Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma

S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland)

Source: Annual Congress 2007 - New treatments for asthma
Session: New treatments for asthma
Session type: Thematic Poster Session
Number: 2115
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland). Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma. Eur Respir J 2007; 30: Suppl. 51, 2115

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019

The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 253s
Year: 2005

The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019

The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 147s
Year: 2001

Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

The influence of high doses of N-acetylcysteine alone or in combination with inhaled corticosteroids on quality of life in patients with COPD
Source: Annual Congress 2011 - COPD management
Year: 2011

Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 54s
Year: 2001

Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001